To provide long term capital appreciation.
Name | % Net Assets |
---|---|
BG Group | 5.0% |
Gilead Sciences | 3.5% |
StatoilHydro ASA | 2.9% |
AXA S.A. | 2.8% |
Credit Suisse Group | 2.8% |
Itau Unibanco Banco Multiplo S.A. ADS | 2.7% |
GlaxoSmithKline | 2.6% |
Astrazeneca | 2.6% |
Lloyds Banking Group | 2.6% |
Merck & Co. | 2.6% |
Key | % Net Assets |
---|---|
![]() |
5.0% |
![]() |
3.5% |
![]() |
2.9% |
![]() |
2.8% |
![]() |
85.8% |
Date | 25-Apr-2025 |
---|---|
NAV | 285.87p |
Currency | GBP |
Change | 5.17p |
% | 1.84% |
YTD change | -26.89p |
YTD % | -8.60% |
Fund Inception | 19/02/2001 |
---|---|
Fund Manager | Derek Lygo |
TER | 0.84 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.04 |
You are here: research